Condition (MeSH)
Scalp Dermatoses
ClinicalTrials.gov lists 34 trials for Scalp Dermatoses or a narrower condition beneath it. L'Oreal has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 of the 34 trials are tagged with Scalp Dermatoses itself; the rest are tagged with a narrower condition beneath it.
When did Scalp Dermatoses trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 9 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 4 |
| 2021 | 2 |
| 2019 | 2 |
| 2017 | 1 |
| 2015 | 2 |
| 2014 | 1 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 34 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Scalp Dermatoses trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 2/3 | 3 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Not applicable | 14 |
| Observational | 10 |
How many Scalp Dermatoses trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Active, not recruiting | 3 |
| Completed | 22 |
| Terminated | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Scalp Dermatoses trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| L'Oreal | 4 |
| Vichy Laboratoires | 2 |
| Cosmetique Active International | 1 |
| Dove Medical Press Ltd | 1 |
| Merz North America, Inc. | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Scalp Dermatoses? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| TERBINAFINE HYDROCHLORIDE (1%) | 3 |
| Itraconazole | 2 |
| Griseofulvin | 1 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo | 1 |
| Cold Cream | 1 |
| K301 | 1 |
| Probiotic | 1 |
| Ketoconazole 2% Foam | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Scalp Dermatoses? (64)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial. | Journal of the American Academy of Dermatology | 2025 | Yes |
| Collateral benefits of ivermectin mass drug administration designed for malaria against headlice in Mopeia, Mozambique: a cluster randomised controlled trial. | Infectious diseases of poverty | 2025 | Yes |
| Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial. | JAMA dermatology | 2025 | Yes |
| Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial. | JAMA dermatology | 2025 | Yes |
| A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris. | American journal of clinical dermatology | 2021 | Yes |
Showing 5 of 64 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.